ArticleInternational journal of clinical oncology2026

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; sevabertinib for lung cancer, gemcitabine intravesical system and durvalumab for bladder cancer, azacitidine for leukemia, cemiplimab for skin cancer, and ropeginterferon alfa-2b for essential thrombocythemia.

Noriomi MatsumuraPubMed ↗Publisher ↗

No numbers read from the abstract.